Skip to content

February 2026

Ayahuasca

What February 2026's 9 new studies found, synthesized from the papers below. All Ayahuasca research →

The synthesis

Synthesized from 9 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Ayahuasca, yage, hoasca, banisteriopsis, then ranked by relevance.

Research published in February 2026 indicates that ayahuasca and its main component DMT show promise for treating mental health conditions, particularly depression and trauma-related fear, with evidence from preclinical studies and reviews suggesting positive effects on neuroplasticity and fear extinction. However, clinical evidence remains largely observational and preliminary, with systematic reviews noting inconsistent long-term outcomes and potential psychiatric complications in some users. The main caveat is the lack of large, randomized controlled trials and the need for further research on safety, dosing, and long-term effects.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.

This review argues that DMT and 5-MeO-DMT show therapeutic potential for treatment-resistant depression and major depressive disorder, with several phase II studies underway.

review

This review summarizes evidence that ayahuasca shows promise for treating multiple mental health disorders by modulating neuroplasticity, inflammation, and stress response, but notes that evidence is mainly observational and randomized trials are needed.

review

This controlled experiment found that ayahuasca prevented the reduction in somatosensory cortex neuronal volume caused by chronic social isolation stress in juvenile male marmosets, suggesting a prophylactic effect.

controlled experiment (social isolation model)

This theoretical study suggests a clinically relevant interaction between ayahuasca and SSRIs, as modest increases in DMT exposure may intensify serotonergic effects in individuals receiving antidepressant therapy.

theoretical or mechanistic framework

This cross-sectional study found no significant group differences in neuropsychological performance between chronic ayahuasca users, cannabis users, and non-users, but personality traits distinguished the groups.

cross-sectional study Sample size: 219

This review of a book on ayahuasca argues that the interdisciplinary approach provides a plural overview of ayahuasca, though it could have more deeply explored traditional knowledge and Indigenous perspectives.

review

This theoretical paper argues that atmosphere serves as a central mechanism in VR for rendering invisible and relational processes tangible, enabling experiences that resonate with mystical-type mental states.

theoretical or philosophical paper

This systematic review of 18 prospective studies found long-term changes in wellbeing, depression, psychiatric symptoms, substance misuse, cognitive flexibility, personality, and prosocial behavior, but also reported subsets of participants with persisting psychiatric complications.

systematic review Sample size: 18

This experimental study found that ayahuasca enhances fear extinction and reduces generalized fear in rats through BDNF-TrkB signaling in the infralimbic cortex.

experimental study

Points of agreement

  • Ayahuasca and DMT show therapeutic potential for mental health conditions, particularly depression and trauma-related fear.
  • Preclinical studies indicate ayahuasca can modulate neuroplasticity and enhance fear extinction.
  • Reviews consistently note that clinical evidence is mainly observational and randomized controlled trials are needed.
  • Chronic ayahuasca use is not associated with lasting neuropsychological impairments.

Conflicts

  • Some studies report mental health improvements, while others note persisting psychiatric complications in subsets of users.
  • The systematic review found mixed long-term outcomes, whereas individual preclinical studies show positive effects.
  • Theoretical and philosophical papers do not directly address clinical efficacy, contrasting with empirical studies.

Gaps

  • Lack of large, randomized controlled trials in humans.
  • Durability of therapeutic effects over long-term follow-up is not well established.
  • Safety and efficacy in specific populations (e.g., adolescents, females, individuals with comorbidities) are understudied.
  • Standardized dosing and controlled settings are missing in many prospective studies.
  • Physical health outcomes are rarely assessed in prospective studies.
  • Potential drug-drug interactions with SSRIs need further investigation.
Browse these studies in the library